Metastatic Neuroendocrine Carcinoma
Also known as: Neuroendocrine carcinoma metastatic / Neuroendocrine carcinoma, metastatic (morphologic abnormality)
Drug | Drug Name | Drug Description |
---|
Drug | Drug Name | Target | Type |
---|
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB04690 | Camptothecin | 1 | Active Not Recruiting | 1 |
DB00762 | Irinotecan | 1 | Active Not Recruiting | 1 |
DB01030 | Topotecan | 1 | Active Not Recruiting | 1 |
DB08875 | Cabozantinib | 2 | Active Not Recruiting | 1 |
DB09130 | Copper | 2 | Enrolling by Invitation | 1 |
DB15873 | Copper oxodotreotide Cu-64 | 2 | Enrolling by Invitation | 1 |
DB14554 | Dotatate | 2 | Enrolling by Invitation | 1 |
DB17969 | Edotreotide | 2 | Withdrawn | 1 |
DB09502 | Fludeoxyglucose (18F) | 2 | Enrolling by Invitation | 2 |
DB06186 | Ipilimumab | 2 | Active Not Recruiting | 1 |
DB13982 | Lutetium Lu-177 | 2 | Withdrawn | 1 |
DB09035 | Nivolumab | 2 | Active Not Recruiting | 2 |
DB00853 | Temozolomide | 2 | Active Not Recruiting | 1 |